Prognostic value of the microRNA-214 in multiple human cancers: a meta-analysis of observational studies

Yajing Feng _, Fujiao Duan, Weigang Liu, Xiaoli Fu, Shuli Cui and Zhenxing Yang

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2017; 8:75350-75360. https://doi.org/10.18632/oncotarget.17642

Metrics: PDF 1515 views  |   HTML 2757 views  |   ?  


Yajing Feng1,4, Fujiao Duan2,6, Weigang Liu3, Xiaoli Fu4, Shuli Cui5 and Zhenxing Yang2

1Department of Nosocomial Infection Management, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China

2Medical Research Office, Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, Henan, China

3Medical Record Statistics Office, Affiliated Hospital of Hebei University of Engineering, Handan, Hebei, China

4College of Public Health, Zhengzhou University, Zhengzhou, Henan, China

5College of Professional Study, Northeastern University, Boston, Massachusetts, USA

6Henan Key Laboratory of Tumor Epidemiology, Zhengzhou, Henan, China

Correspondence to:

Yajing Feng, email: [email protected]

Fujiao Duan, email: [email protected]

Keywords: miR-214, cancer, prognosis, systematic evaluation

Received: February 04, 2017    Accepted: April 07, 2017    Published: May 06, 2017


Previous studies showed that microRNA-214 (miR-214) may act as a prognostic biomarker of cancer. However, the available evidence is controversial. This study summarizes evidence and evaluates the prognostic role of miR-214 in various cancers. We carried out a systematic literature review and assessed the quality of included studies based on Oxford Centre for Evidence-based Medicine Criteria and Newcastle-Ottawa Scale (NOS). Pooled hazard ratios (HRs) with corresponding 95% confidence intervals (CIs) for overall survival (OS) and disease free survival/progressive free survival/recurrence free survival (DFS/PFS/RFS) were calculated to measure the effective value of miR-214 expression on prognosis. Thirteen studies were included in pooled analysis. We found that miR-214 was significantly correlated with OS (HR=2.21, 95%CI: 1.33-3.68, P=0.00), no significant difference was found with DFS/PFS/RFS (HR=1.73, 95%CI: 0.78-3.83, P=0.18) in various carcinomas. In subgroup analysis, higher expression of miR-214 was significantly associated with poor OS in Asians (HR=2.27, 95%CI: 1.09-4.73, P=0.00) and Caucasians (HR=2.04, 95%CI: 1.47-3.30, P=0.00). On the contrary, high miR-214 expression significantly predicted favorable DFS/PFS/RFS (HR=0.50, 95%CI: 0.31-0.82, P=0.00) in hepatocellular carcinoma (HCC) group. Our data indicates that high miR-214 could be a promising biomarker for prognosis prediction of cancer. However, further clinical studies are needed for the current insufficient relevant data.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 17642